Program
HS-10506
A development code. Also written as “HS-10506, Itraconazole”.
In Hansoh Pharmaceutical Group's pipeline, OX2R antagonist
. Its studies are mostly in Sleep Initiation and Maintenance Disorders · Lymphoma, Follicular, led by Hansoh Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 66 open or running | phase 3since Apr 23, 2026 | Jun 26, 2023 | Jun 1, 2028phase 1 · NCT07844967 |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
HS-10506 (OX2R antagonist)
, phase 3, as of Aug 26, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 26, 2023First study: phase 1 study in HealthyFirst studyNCT05953506 · 52 planned
- Feb 18, 2024Phase 2 study in Sleep Initiation and Maintenance DisordersNCT06279286 · 312 planned · China
- Mar 20, 2026Phase 1 study in Healthy ParticipantsNCT07535970 · 20 planned · China
- Apr 23, 2026Phase 3 study in Sleep Initiation and Maintenance DisordersPhase 3 reachedNCT07587385 · 732 planned
- Jun 8, 2026Phase 3 study in Sleep Initiation and Maintenance DisordersNCT07677384 · 600 planned
- Jul 8, 2026Phase 1 study in Lymphoma, FollicularNCT07844967 · 32 planned · China
Ahead
- Jun 1, 2028Primary completion: phase 1 study in Lymphoma, FollicularNCT07844967
- Jun 28, 2028Primary completion: phase 3 study in Sleep Initiation and Maintenance DisordersNCT07587385
- Jun 30, 2029Primary completion: phase 3 study in Sleep Initiation and Maintenance DisordersNCT07677384
TargetBeta
“OX2R antagonist”the company's pipeline, read by Claude · source
Other programs on HCRTR2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daridorexantrule | Idorsia Pharmaceuticals | phase 4 | 34 |
| seltorexantrule | Johnson & Johnson | phase 3 | 33 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07844967Lymphoma, Follicular · China | 1 | Recruiting | Jun 1, 2028 | 32 |
| NCT07677384Sleep Initiation and Maintenance Disorders | 3 | Not yet recruiting | Jun 30, 2029 | 600 |
| NCT07587385Sleep Initiation and Maintenance Disorders | 3 | Not yet recruiting | Jun 28, 2028 | 732 |
| NCT07535970Healthy Participants · China | 1 | Not yet recruiting | Jul 30, 2026 | 20 |
| NCT06279286Sleep Initiation and Maintenance Disorders · China | 2 | Not yet recruiting | Jan 2025 | 312 |
| NCT05953506Healthy | 1 | Not yet recruiting | Dec 24, 2023 | 52 |
How it is read
Names in the registry
- “HS-10506”, 5 entries
- “HS-10506, Itraconazole”, 1 entry
Codes read as this program: HS10506.
Conditions, from the studies’ own filings
- Sleep Initiation and Maintenance Disorders, 3 studies
- Lymphoma, Follicular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.